DBV Technologies S.A. (DBVT)
|Net Income (ttm)||-75.79M|
|Day's Range||1.33 - 1.40|
|52-Week Range||1.08 - 3.43|
|Price Target||2.92 (+116.3%)|
|Earnings Date||Mar 2, 2023|
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin... [Read more]
In 2021, DBVT's revenue was 5.71 million, a decrease of -49.38% compared to the previous year's 11.28 million. Losses were -97.81 million, -38.70% less than in 2020.Financial numbers in EUR Financial Statements
According to 10 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is $2.92, which is an increase of 116.30% from the latest price.
AMF Regulated Information Montrouge, France, January 23, 2023
The FDA lifts the partial clinical hold on DBV Technologies' (DVBT) phase III VITESSE study of a modified Viaskin Peanut patch in peanut-allergic children aged four to seven years. Stock rises.
Montrouge, France, December 23, 2022
Montrouge, France, November 22, 2022
Montrouge, France, November 9, 2022
Montrouge, France, November 3, 2022
Montrouge, France, October 31, 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DBV Technologies S.A. - DBVT
NEW YORK , Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of DBV Technologies S.A. - DBVT
New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of DBV Technologies S.A. (""DBV" or the "Company") (NASDAQ: DBVT). Such investors ...
DBV Technologies Announces Appointment of New Chair of its Audit Committee and Appointment of Daniele Guyot-Caparros to Board of Directors
Montrouge, France, October 3, 2022
DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA.
Montrouge, France, September 21, 2022
DBV Technologies Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years
Montrouge, France, September 7, 2022
Montrouge, France, September 2, 2022
Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
Montrouge, France, August 1, 2022
Montrouge, France, June 28, 2022
Montrouge, France, June 16, 2022
Here is how DBV Technologies S.A. (DBVT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.
Montrouge, France, June 9, 2022
HC Wainwright believes the most significant takeaway from DBV Technologies SA's (NASDAQ: DBVT) trial update was that 250ug treatment achieved the primary endpoint of difference between the percentage ...
DBV Technologies SA's (NASDAQ: DBVT) pivotal Phase 3 EPITOPE trial of Viaskin Peanut 250 µg for peanut-allergic toddlers ages 1 to 3 years met its primary endpoint. Viaskin Peanut demonstrated a stat...
DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers
Montrouge, France, June 7, 2022
Montrouge, France, May 12, 2022
DBV Technologies Completes ADSs Sale of an amount of $15.3 million on Nasdaq through its At-The-Market program (ATM)
Montrouge, France, May 5, 2022